Chris Hansis, MD, PhD
Founder & CEO
Dr. Chris Hansis is the Founder & CEO of Phase Clinical Services, a full service CRO in Manhattan concentrating on Phase 0-II oncology clinical trials. Previously he was the Founder & CEO of the preclinical research services provider TransCell Science until its acquisition by BioIVT, for which he served as the Chief Scientific Officer. He was also Research Faculty, Principal Investigator and Director at the University of Southern California and New York University Medical Schools, focusing on generation of human embryonic stem and iPS cells and molecular lineage determination in preimplantation embryos.
David J. Gibboni, PhD, MBA
Dr. David Gibboni is heading Business Development at Phase Clinical Services. Previously he was the Senior Director and Vice President of Business Development at Invicro (a Konica Minolta company providing global imaging services). Prior, he served as Senior Director of Business Development at WorldCare Clinical (a global imaging CRO). He also served as Director of Business Development for 5 years at ICON (a top 100 CRO) and Business Development Manager at Air Liquide Healthcare. David holds a PhD degree in organometallic chemistry from Yale University and an MBA from Saint Joseph’s University.
Xiaomei Wang, MD, PhD
Dr. Xiaomei Wang is heading Scientific Affairs at Phase Clinical Services. She completed postdoctoral studies at The Children’s Hospital of Philadelphia, Department of Hematology. Amongst other prizes, she was awarded First Prize for Excellence in Research at the Fels Institute for Cancer Research and Molecular Biology at Temple University School of Medicine, where she also completed her PhD in Molecular and Cellular Biology. Xiaomei obtained an MD degree from Peking University Health Science Center and worked as a Research Assistant at Peking Union Medical College Hospital, both of which are top institutions in China.
We welcome the opportunity to discuss your oncology clinical trial needs and prepare a free feasibility study for you. Contact us.